Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction

Blood Pressure

Volumn 11, Issue 6, 2002, Pages 377-384

  Jonsson, Gisli ^a   Fossum, Eigil ^a   Kjeldsen, Sverre E ^a   Høieggen, Aud ^a   Os, Ingrid ^a   Eide, Ivar ^a   Westheim, Arne ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adrenaline; Atenolol; Blood flow; Carvedilol; Hemorrheology; Insulin sensitivity; Myocardial infarction; Sympathetic nervous system; Vasopressin

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; ENALAPRIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOPROLOL; NORADRENALIN; VASOPRESSIN;

ACUTE HEART INFARCTION; ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FOREARM BLOOD FLOW; GLUCOSE CLAMP TECHNIQUE; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; HYPERINSULINISM; MALE; NORADRENALIN BLOOD LEVEL; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR RESISTANCE; VASCULARIZATION; VASOPRESSIN BLOOD LEVEL;

ADRENERGIC ALPHA-ANTAGONISTS; ATENOLOL; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD VISCOSITY; CARBAZOLES; EPINEPHRINE; FEMALE; FOREARM; GLUCOSE CLAMP TECHNIQUE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NOREPINEPHRINE; PROPANOLAMINES; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE;

EID: 0036931764     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370502321095357     Document Type: Review

References (43)

1. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. J Clin Pharmacol 1990; 38 Suppl 2: S82-8.
2. Nichols AJ, Gellai M, Ruffolo RR Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 1991; 5: 25-38.
3. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989; 39: 327-40.
4. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-8.
5. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo R. Myocardial protection by novel vasodilating beta blocker, carvedilol - potential relevance of antioxidant activity. J Hypertens 1993; 11 Suppl 4: 41-8.
6. Yue TL, McKenna PJ, Lysko PG, Ruffolo R, Feuerstein GZ. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992; 97: 209-16.
7. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21: 221-7.
8. Albrightson CR, Zabko-Potapovich B, Brooks DP. Effect of carvedilol on mitogen-stimulated mesangial cell proliferation. Pharmacol Commun 1992; 1: 267-72.
9. Hoffman BB, Lefkowitz RJ. Catecholamines, sympatomimetic drugs, and adrenergic receptor antagonists. In: Goodman & Gilman's Pharmacological Basis of Therapeutics, 9th edition. New York: McGraw-Hill, 1996: chap. 10, 238.
10. Hjalmarsson Å. Prevention of sudden cardiac death with beta blockers. Clin Cardiol 1999; 22 Suppl V: V-11-15.
11. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac β-adrenergic receptors, and heart failure. Circulation 2000; 101: 1634-7.
12. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997; 96: 183-91.
13. Sandvik L, Erikssen J, Mowinchel P, Rødland EA. A method for determining the size of internal pilot studies. Stat Med 1996; 15: 1587-90.
14. Moan A, Nordby G, Os I, Birkeland KI, Kjeldsen SE. Relationship between hemorrheologic factors and insulin sensitivity in healthy young men. Metabolism 1994; 43: 423-7.
15. Fossum E, Høieggen A, Moan A, Nordby G, Kjeldsen SE. Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinemic, isoglycemic glucose clamp technique. Blood Press 1997; 6: 113-19.
16. Hokanson DE, Sumner DS, Strandness DE. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 1975; 22: 25-9.
17. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 1977; 21: 625-36.
18. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension. Scand J Clin Lab Invest 1982; 42: 217-23.
19. Os I, Kjeldsen SE, Aakesson I, et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension 1986; 8: 506-13.
20. Høieggen A, Fossum E, Moan A, Enger E, Kjeldsen SE. Whole-blood viscosity and the insulin resistance syndrome. J Hypertens 1998; 16: 203-10.
21. Fossum E, Høieggen A, Moan A, Nordby G, Velund TL, Kjeldsen SE. Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors. Blood Press 1997; 6: 161-5.
22. Devreese K, Leroux-Roels G. Laboratory assessment of five glucose meters designed for self monitoring of blood glucose concentration. Eur J Clin Chem Clin Biochem 1993; 31: 829-37.
23. Rostrup M, Kjeldsen SE, Eide I. Awareness of hypertension increases blood pressure and sympathetic responses to cold pressor test. Am J Hypertens 1990; 3: 912-17.
24. DG Altman. Practical statistics for medical research. Chapman & Hall, 1991: 431-3.
25. Moan A, Høieggen A, Nordby G, Birkeland K, Eide I, Kjeldsen SE. The glucose clamp procedure activates the sympathetic nervous system even in absence of hyperinsulinemia. J Clin Endocrinol Metab 1995; 80: 3151-4.
26. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997; 80: 15-25L.
27. Heibrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79; 483-90.
28. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-25.
29. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: 26-40L.
30. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998; 41 Suppl 1: 39-52.
31. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepineprine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
32. Kesmarky G, Toth K, Habon L, Vajda G, Juricskay I. Hemorheological parameters in coronary artery disease. Clin Hemorheol Microcirc 1998; 18: 245-51.
33. Willich SN, Maclure, M, Mittlemann M, Arntz H-R, Muller JE. Sudden cardiac death: support for a role of triggering in causation. Circulation 1993; 87: 1442-50.
34. Zelis R, Flaim SF. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 1982; 24: 437-59.
35. Creager MA, Faxon DP, Sally S, et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. JACC 1986; 7: 758-65.
36. Sharpe N, Smith H, Murphy J, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255-9.
37. Pfeffer MA, Lamas GL, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-6.
38. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 1724-9.
39. Kennedy HL. Beta blockade, ventricular arrythmias, and sudden cardiac death. Am J Cardiol 1997; 80: 29-34J.
40. Giles TD. Factors affecting circadian variability. Blood Press Monit 2000; 5: S3-7.
41. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14: 489-94.
42. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14: 175-80.
43. Everson SA, Kaplan GA, Goldberg DE, Salonen JT. Anticipatory blood pressure response to exercise predicts future high blood pressure in middle-aged men. Hypertension 1996; 27: 1059-64.